EP0979309A4 - Oligonukleotide mit verbesserter bioverfügbarkeit - Google Patents

Oligonukleotide mit verbesserter bioverfügbarkeit

Info

Publication number
EP0979309A4
EP0979309A4 EP98920076A EP98920076A EP0979309A4 EP 0979309 A4 EP0979309 A4 EP 0979309A4 EP 98920076 A EP98920076 A EP 98920076A EP 98920076 A EP98920076 A EP 98920076A EP 0979309 A4 EP0979309 A4 EP 0979309A4
Authority
EP
European Patent Office
Prior art keywords
oligonucleotides
better bioavailability
alimentary delivery
oligonucleotide
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98920076A
Other languages
English (en)
French (fr)
Other versions
EP0979309A1 (de
Inventor
Nicholas M Dean
C Frank Bennett
Brett P Monia
Kenneth Draper
Kevin P Anderson
Brenda F Baker
David J Ecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of EP0979309A1 publication Critical patent/EP0979309A1/de
Publication of EP0979309A4 publication Critical patent/EP0979309A4/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
EP98920076A 1997-04-30 1998-04-30 Oligonukleotide mit verbesserter bioverfügbarkeit Ceased EP0979309A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US847151 1992-03-05
US84715197A 1997-04-30 1997-04-30
PCT/US1998/008798 WO1998049348A1 (en) 1997-04-30 1998-04-30 Oligonucleotides for enhanced bioavailability

Publications (2)

Publication Number Publication Date
EP0979309A1 EP0979309A1 (de) 2000-02-16
EP0979309A4 true EP0979309A4 (de) 2000-10-18

Family

ID=25299899

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98920076A Ceased EP0979309A4 (de) 1997-04-30 1998-04-30 Oligonukleotide mit verbesserter bioverfügbarkeit

Country Status (6)

Country Link
EP (1) EP0979309A4 (de)
JP (1) JP2000514095A (de)
KR (1) KR20010020370A (de)
AU (1) AU738352B2 (de)
CA (1) CA2286396C (de)
WO (1) WO1998049348A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
JP2002515513A (ja) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド 核酸の肺送達のための組成物および方法
PT1077722E (pt) 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
JP2002537343A (ja) * 1999-02-23 2002-11-05 アイシス・ファーマシューティカルス・インコーポレーテッド 多重粒子製剤
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6168950B1 (en) * 1999-07-23 2001-01-02 Isis Pharmaceuticals, Inc. Antisense modulation of MEKK1 expression
US6677445B1 (en) 1999-08-27 2004-01-13 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
WO2001016306A2 (en) * 1999-08-27 2001-03-08 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
EP1322655B1 (de) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
JP4999255B2 (ja) 2001-07-10 2012-08-15 レイクウッド−アメディックス，インコーポレーテッド オリゴヌクレオチド含有薬理学的組成物およびその使用
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0626387A1 (de) * 1993-05-12 1994-11-30 Ciba-Geigy Ag Nukleoside und Oligonukleotide mit 2'-Ethergruppen
WO1995002069A1 (en) * 1993-07-09 1995-01-19 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase c
WO1996012497A1 (en) * 1994-10-25 1996-05-02 Hybridon, Inc. Use of 2'-substituted oligonucleotides to down-regulating gene expression
WO1997004787A1 (en) * 1995-08-01 1997-02-13 Novartis Ag Liposomal oligonucleotide compositions
WO1997029780A1 (en) * 1996-02-14 1997-08-21 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase c expression

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214135A (en) * 1991-08-30 1993-05-25 Chemgenes Corporation N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0626387A1 (de) * 1993-05-12 1994-11-30 Ciba-Geigy Ag Nukleoside und Oligonukleotide mit 2'-Ethergruppen
WO1995002069A1 (en) * 1993-07-09 1995-01-19 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase c
WO1996012497A1 (en) * 1994-10-25 1996-05-02 Hybridon, Inc. Use of 2'-substituted oligonucleotides to down-regulating gene expression
WO1997004787A1 (en) * 1995-08-01 1997-02-13 Novartis Ag Liposomal oligonucleotide compositions
WO1997029780A1 (en) * 1996-02-14 1997-08-21 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase c expression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARTIN P: "38. EIN NEUER ZUGANG ZU 2'-O-ALKYLRIBONUCLEOSIDEN UND EIGENSCHAFTEN DEREN OLIGONUCLEOTIDE", HELVETICA CHIMICA ACTA,CH,VERLAG HELVETICA CHIMICA ACTA. BASEL, vol. 78, 1995, pages 486 - 504, XP000857415, ISSN: 0018-019X *
See also references of WO9849348A1 *

Also Published As

Publication number Publication date
EP0979309A1 (de) 2000-02-16
WO1998049348A1 (en) 1998-11-05
KR20010020370A (ko) 2001-03-15
JP2000514095A (ja) 2000-10-24
CA2286396C (en) 2010-07-06
AU7272398A (en) 1998-11-24
AU738352B2 (en) 2001-09-13
CA2286396A1 (en) 1998-11-05

Similar Documents

Publication Publication Date Title
WO2005030259A3 (en) Nucleic acid-lipophilic conjugates
EP0979309A4 (de) Oligonukleotide mit verbesserter bioverfügbarkeit
MXPA02010787A (es) Peptidos modificados como agentes terapeuticos.
BR0115810B1 (pt) composições cosméticas, dermatológicas e farmacêuticas isentas de tensoativos.
WO2007008463A3 (en) Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
ZA200202996B (en) Hair treatment compositions comprising particulate substances.
WO2001080840A3 (en) Cytotoxic agents comprising single-stranded and/or looped dna
TR199800631A3 (tr) Ecza formülasyonu.
GB9807256D0 (en) Functional protein compositions,emulsions based thereon and processes for their preparation
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
MXPA01011137A (es) Inmunizacion genetica no invasiva, productos de la expresion a partir de esta, y sus usos.
MXPA03007314A (es) Composicion para la piel para reducir aceites y grasa de la piel.
EP1617735A4 (de) Zusammensetzung von bzw. verfahren für funktionelles tiermuskelprotein mit niedrigem cholesteringehalt
ZA200109845B (en) Hair treatment compositions.
WO2001014415A3 (en) Egfh2 genes and gene products
WO2004029075A3 (en) Peptide nucleic acids having improved uptake and tissue distribution
AU6082800A (en) Edible animal muscle protein gels
ES1039279Y (es) Producto de confiteria.
WO2002070557A3 (en) Nuclear hormone receptor ligand binding domain
IT1295647B1 (it) Apparecchiatura per incartare prodotti di medie dimensioni, in particolare prodotti dolciari.
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
DK1023823T3 (da) Landbrugsfordelermaskine.
EP1373291A4 (de) Antisense-modulierung der recql4 expression
ZA996211B (en) Functional protein compositions, emulsions based thereon and processes for their preparation.
ITTO20010186U1 (it) ,,supporto veicolare profumi e prodotti similari,,.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ECKER, DAVID, J.

Inventor name: BAKER, BRENDA, F.

Inventor name: ANDERSON, KEVIN, P.

Inventor name: DRAPER, KENNETH

Inventor name: MONIA, BRETT, P.

Inventor name: BENNETT, C., FRANK

Inventor name: DEAN, NICHOLAS, M.

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12Q 1/68 A, 7C 12N 15/00 B, 7C 12N 15/63 B, 7C 12N 5/06 B, 7C 07H 21/00 B, 7C 07H 21/04 B, 7A 61K 48/00 B, 7A 61K 31/70 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000830

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030124

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ISIS PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20050401